Navigation Links
Small assist device used in emergency case as twin, heart booster pumps for first time in US
Date:11/12/2010

The Bluhm Cardiovascular Institute of Northwestern Memorial Hospital recently implanted a patient with two of the smallest experimental ventricular assist devices (VADs) currently available for study in humans. VADs are designed to assist either the right (RVAD) or left (LVAD) ventricle, or both (BiVAD) at once. This is the first time that two Heartware VADs have been implanted in the left and right ventricles anywhere in North Americaa "game changer" in the realm of heart assist devices according to Patrick M. McCarthy, MD, chief of the hospital's Division of Cardiac Surgery and director of the hospital's Bluhm Cardiovascular Institute.

"The world doesn't need the artificial heart anymore," said Dr. McCarthy, who is also the Heller-Sacks Professor of Surgery at Northwestern University Feinberg School of Medicine. "The goal is total support of the heart. This biventricular approach achieves that without cutting out the patient's own heart, which is what happens with artificial heart implants."

According to Edwin C. McGee, Jr. MD, surgical director for the Bluhm Institute's Heart Transplant and Assist Device program and the lead cardiac surgeon who performed the implant, when the patient, 44-year-old James Armstrong, was transferred to Northwestern Memorial just weeks ago, he was near death with an aggressive state of myocarditis. Myocarditis is a severe inflammation of the heart tissue thatin some rare casescan be fatal when unaddressed.

Only about a dozen times before in Europe had the twin implant of the small Heartware VAD been performed, and now the approach would be Armstrong's best chances for survival. The Heartware VAD is under trial in the U.S. as an LVAD. Mr. Armstrong did not qualify for the current trial and was able to have the device implanted under a process known as "emergency use". Emergency use is defined as the use of an investigational article with a human subject in a life-threatening situation. Although such uses are not yet approved by the U.S. Food and Drug Administration, they are allowed when there is no standard acceptable treatment available and there is not sufficient time to obtain approval from an Institutional Review Board.

"As we do for all of our patients, we wanted the very best for Jim," said McGee. "Standard BiVAD pumps sit outside of the body and are plagued by an extremely high complication and mortality rate."

McGee added that another reason to study this system is because the configuration leaves patients' hearts intact. This, he says, lends itself to the possibility that in some rare cases the heart may actually recover. "Naturally, that remains to be seenbut it's possible," he says. This probability is obliterated with artificial hearts because essential components of the natural heart are removed.

McGee adds that one of the greatest advantages to patients is that the pumps are contained (implanted) completely within the chest. There are two small controlling leads in the body that connect to a small monitor and power source outside the body that can be carried in two small shoulder pouches.

"Using this device in a biventricular support configuration may offer total heart support to more individuals with improved quality of life and hopefully fewer complications, than with the currently approved devices," added McGee.


'/>"/>

Contact: Kris Lathan
klathan@nmh.org
312-926-2963
Northwestern Memorial Hospital
Source:Eurekalert

Related medicine news :

1. Unexpectedly small effects of mutations in bacteria bring new perspectives
2. UCI non-small cell lung cancer study highlights advances in targeted drug therapy
3. Small particles show big promise in beating unpleasant odors
4. Small business success spotlighted by USDA at conference
5. American Chemical Society Webinar focuses on NSFs small business funding programs
6. Health Care Reform Helps Small Businesses Offer Coverage: Report
7. 16.6 million small business employees could benefit from ACA provisions starting this year
8. Babies Born Late May Face Small Cerebral Palsy Risk
9. Small Amounts of Dark Chocolate May Guard Against Heart Failure
10. Henry Ford Hospital study: Donor Risk Index does not impact outcomes on a small scale
11. Small increases in vaccine cost can cause large gaps in protection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... , ... Mediaplanet is proud to announce the launch of its newest edition ... readers on how to take care of all aspects of their skin. , On ... Dancing with the Stars professional, Witney Carson, shares her journey with the disease that ...
(Date:5/26/2017)... ... May 26, 2017 , ... The Radiology Business Management ... on current legislative activity and the latest regulatory concerns impacting RBMA members. The ... 10, and will continue through Monday, Sept. 11, at the Ritz-Carlton, Tysons Corner ...
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of community health ... seniors are located in the Midwest. With the average cost of healthcare rising and ... concerned with both the quality and affordability of where they live. An annual 2017 ...
(Date:5/26/2017)... ... 26, 2017 , ... On May 24, the Congressional Budget Office (CBO) projected ... on May 4, would result in 23 million Americans losing their health insurance by ... Patient Protection and Affordable Care Act (ACA). , “It is clear from the ...
(Date:5/26/2017)... ... ... Silver Birch of Hammond, a new assisted lifestyle community, has welcomed its first ... at 5620 Sohl Avenue in Hammond, serves older adults who need some help to ... apartments. Each of the private apartments at Silver Birch features a kitchenette, spacious bathroom ...
Breaking Medicine News(10 mins):
(Date:5/23/2017)... PLEASANTON, Calif. , May 23, 2017 /PRNewswire/ ... world,s most innovative medical devices for pressure ulcer ... at the American Association of Critical Care Nurses, ... Houston May 22-25. The Leaf Patient ... designed specifically for the hospital environment.  The system ...
(Date:5/18/2017)... May 17, 2017  Bayer announced today that the ... be presented at the 53 rd Annual Meeting ... place June 2-6 in Chicago . ... span prostate, colorectal, liver and thyroid cancers, as well ... Phase II CHRONOS-1 trial of copanlisib in patients with ...
(Date:5/11/2017)...  Thornhill Research Inc. ( Toronto, Ontario, ... USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract by the U.S. ... (CCC) ( Ottawa, Ontario, Canada ) ... anesthesia to patients requiring emergency medical procedures in ... Corps have been a longtime partner with Thornhill ...
Breaking Medicine Technology: